menu ☰
menu ˟

Ralinepag may improve pulmonary vascular resistance in patients with PAH

11 Jul 2017
Arena Pharmaceuticals announced that phase 2 results from a study of ralinepag showed an absolute change in pulmonary vascular resistance in patients with pulmonary artery hypertension.“PAH is a complex and serious disease, often with a poor progno...

Click here to view the full article which appeared in Cardiology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.